MORRISVILLE, N.C., May 20 /PRNewswire/ --Asymchem Laboratories, Inc., a leading research-based contract manufacturer of API's, intermediates and Drug Products to the pharmaceutical industry, with sites in the U.S. and China, is pleased to announce the recent addition of Dr. Chris Huber as Director of Chemical Development.
Dr. Huber brings to the table over 15 years experience in the pharmaceutical industry (early and late stage), developing process technology for API manufacturing of small molecules. Prior to Asymchem, Dr. Huber directed early phase projects for API manufacturing at Achaogen Inc. and Arena Pharmaceuticals. Much of his career was spent in Pfizer and legacy companies in process chemistry, with focus on optimization, characterization and validation of Phase 3 processes in preparation for commercial manufacturing of API.
As Director of Chemical Development, Dr. Huber will help expand and strengthen Asymchem's pilot scale-up, tech transfers and production efforts into commercial manufacturing. He will report directly to Dr. Jim Gage, VP of Chemical Development.
"I am very pleased to have Dr. Huber on board to help expand and strengthen Asymchem's already well-established large scale manufacturing services," states Dr Hao Hong, CEO of Asymchem. "With his broad experience in the pharmaceutical industry and proven track record of API manufacturing, I am confident that our commercial capabilities will be further strengthened and solidified."
Dr. Huber received his B.S. and M.S. at the Universitat Regensburg , Germany under the supervision of Professors Dr. Henri Brunner, Dr. Jurgen Sauer and Dr. Josef Barthel. He earned his Ph.D. in Organic Chemistry and Catalysis from the Universitat Regensburg, Germany with Professor Dr. Henri Brunner. He did his post doc at
|SOURCE Asymchem Laboratories|
Copyright©2009 PR Newswire.
All rights reserved